Transaction · 0001464583-26-000010

Megna Michael R

Megna Michael R, CAO, reported an open-market or private sale at Kiniksa Pharmaceuticals International, plc involving 6831.000000 shares for an estimated $633711.87. Reported holdings after the transaction were 36096.000000 shares. The stored filing text includes a detected 10b5-1 reference.

Open-market sellSEC transaction code SCAO
KNSAKiniksa Pharmaceuticals International, plc
Trade date
Oct 30, 2026
Filing date
Nov 03, 2026
View on SEC Insider profile
Disclosed value-$633kShares × reported price
Shares traded6.83k$92.77 per share
Holdings after36.0kDirect
% of reported position traded15.91%This security and ownership context
How reported position traded is calculated

Shares sold ÷ (holdings after + shares sold). Estimated position before: 42,927 shares.

Row-level estimate for this security and ownership context, not the insider’s complete portfolio. Joint ownership, other transactions in the filing, amendments and footnotes can affect interpretation.

KNSA price since this filing

Daily closing prices, with the filing date and available return windows
KNSA · Daily closing priceLoading daily prices…
Filing dateReturn windows appear as prices become available.
Pre-filing1mo ago -21.6%1w ago -19.4%1d ago +0.0%
Returns since7d30d90d180d1y

Transaction facts

Stored Form 4 columns with their raw values

Non-derivative
Type
Sell
Code S
Identifier
0001464583-26-000010
Class A Ordinary Share
Transaction date
Oct 30, 2026
Filed Nov 03, 2026, 11:26 PM · 4d delay
Shares
6,831 sh
$92.77 per share
Estimated value
-$633k
Computed from shares × price
Holdings after
36,096 sh
Direct

Filing signal explanations

Badges describe filing facts only — not predictions.

Cluster 14dRepeat 30dPattern $100kLarge $1.00M
Direct Ownership Repeat Seller 10b5-1 Detected
Filing-only score

-4 points

Compact filing score computed from stored Form 4 facts. Version v1.

Neutral filing signal

This filing is broadly neutral on the filing-only scale. The Form 4 facts do not strongly tilt positive or negative.

How this score is calculated
  • direct_ownership+6 points

    direct_or_indirect_ownership = D

    Direct ownership reports the insider's personal stake.
  • tenb5_1_detected-10 points

    is_10b5_1 = true

    Stored filing content includes detected 10b5-1 language.
Read the scoring methodology

Signed filing-only points, not a probability or expected return. Version v1.

Reported relationships & other filings

Form 4 relationship flags and nearby filing context

Reported roles

CHIEF ACCOUNTING OFFICER

Officer YesDirector No10% NoOther No
Footnotes & amended
  1. F1

    This transaction was effected pursuant to a 10b5-1 plan executed by the reporting person on July 30, 2026.

  2. F2

    This transaction was executed in multiple trades through a broker-dealer at prices ranging between $91.275 and $92.26. The price reported in this column reflects a weighted average sales price. Upon r…

  3. F3

    This transaction was executed in multiple trades through a broker-dealer at prices ranging between $92.28 and $93.27. The price reported in this column reflects a weighted average sales price. Upon re…

  4. F4

    This transaction was executed in multiple trades through a broker-dealer at prices ranging between $93.42 and $94.38. The price reported in this column reflects a weighted average sales price. Upon re…

  5. F5

    This transaction was executed in multiple trades through a broker-dealer at prices ranging between $94.42 and $95.22. The price reported in this column reflects a weighted average sales price. Upon re…

  6. F6

    This transaction was executed in multiple trades through a broker-dealer at prices ranging between $95.485 and $96.405. The price reported in this column reflects a weighted average sales price. Upon…

  7. F7

    This transaction was executed in multiple trades through a broker-dealer at prices ranging between $96.565 and $97.50. The price reported in this column reflects a weighted average sales price. Upon r…

  8. F8

    This transaction was executed in multiple trades through a broker-dealer at prices ranging between $97.60 and $98.48. The price reported in this column reflects a weighted average sales price. Upon re…

  9. F9

    The option is fully vested and exercisable.

  10. F10

    The option vests and becomes exercisable as to 25% of the total grant on the first anniversary of the vesting commencement date and vests in 36 equal monthly installments thereafter. The vesting comme…

  11. F11

    The option vests and becomes exercisable as to 25% of the total grant on the first anniversary of the vesting commencement date and vests in 36 equal monthly installments thereafter. The vesting comme…

Original filing · 0001464583-26-000010
Related transactions

0 other transactions

Same SEC filing
Recent company activity

0 recent txs

KNSA